Gene Therapy for Chinese Hemophilia A

Not Applicable

Recruiting

• Conditions: Gene Therapy; Hemophilia A
• Interventions: Genetic: Injection of GS001

• Registration Number: NCT04728841
• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Brief Summary

IHBDH-GTHA-2020 is an open- label, non- randomized study to evaluate the safety, tolerability and kinetics of a single intravenous infusion of GS001 in hemophilia A subjects with \<1 IU/dl residual FVIII levels.

Detailed Description

IHBDH-GTHA-2020 is a open- label, non- randomized study to evaluate the safety, tolerability and kinetics of GS001 in hemophilia A subjects with residual FVIII levels\<1 IU/dl. The first patient will receive a single intravenous infusion of GS001 at a dose level of 2 x 10\^12 vg/kg body weight. After three weeks of follow-up for the first patient post infusion of GS001, the dose of GS001 can be adjusted for the other two patients based on the activity level of FVIII:C and safety assessment. Following completion of the first 3 patients received GS001 infusion at 2 x 10\^12 vg/kg dose level , the following 3 patients will continue to be enrolled to this dose group if there isn't any unexpected safety risk based on the assessments of FVIII expression and safety profile. The safety data and the activity level of FVIII:C from the first 6 subjects at 2 x 10\^12 vg/kg dose level will undergo review by an independent DMC prior to dosing the first subject in the next dose level, DMC may recommend dose escalation to 6 x 10\^12 vg/kg body weight or other recommended dose levels.

If the DMC recommends dose escalation to 6 x 10 \^12 vg/kg body weight or other recommended doses, at least 10 weeks of safety data and the activity level of FVIII:C post GS001 infusion from the first 3 subjects in this given dose level will undergo review by an independent DMC prior to dosing the following subjects. Based on the data from the first 3 subjects, DMC may recommend the dose adjustments for subsequent enrolled subjects, and expand the number of subject enrolled. Based on the safety, preliminary efficacy and vector kinetics profile of single intravenous infusions of GS001 at different dose levels in severe hemophilia A patients with endogenous factor FVIII activity levels ≤ 1% in this study, and based on the benefit-risk assessment of the subjects, the dose level to be administered for future larger clinical trial in patients with severe hemophilia A will be determined.

After all enrolled subjects have been followed for at least 12 weeks after intravenous infusion GS001, periodic analysis will be performed. Primary analysis of safety and efficacy will be performed 52 (± 2) weeks after intravenous infusion GS001, and all subjects will receive 52 (± 2) weeks of comprehensive safety and efficacy assessments. After completing the 52 (± 2) week visit (end-of-study visit), subjects will continue to be followed in this study for up to an additional 4 years for long-term safety and efficacy assessment to evaluate the long-term safety and efficacy of GS001 treatment.

A total of 12 to 15 subjects are expected to be enrolled in this study. Subjects will provide informed consent and then undergo screening assessments up to 4-8 weeks prior administration of GS001. All subjects will undergo 260 weeks (5 years) safety observation.

Study Timeline

• Study First Submitted: 2021-01-25
• Study First Submitted QC: 2021-01-27
• Study First Posted: 2021-01-28
• Study Start: 2021-03-04
• Status Verified: 2025-01
• Last Update Submitted: 2025-02-20
• Last Update Posted: 2025-02-24
• Primary Completion: 2028-07-31
• Study Completion: 2028-07-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Male
• Target Recruitment: 12

Inclusion Criteria

1. Be able to understand the purpose and risks of the study and provide informed consent according to national and local privacy laws;

2. Male subjects and ≥ 18 years of age;

3. Have hemophilia A with ≤1 IU/dL (≤1%) endogenous FVIII activity levels at the time of screening. If the screening result is >1% due to previous treatment with FVIII product, then it may be confirmed by documented historical evidence from a certified clinical laboratory demonstrating ≤1% FVIII activity levels ;

4. Have had ≥150 prior exposure days (EDs) to any recombinant and/or plasma-derived FVIII protein products;

5. Subjects have been on prophylactic exogenous FVIII therapy or on-demand exogenous FVIII therapy in the year prior to screening:

   1. Prophylaxis subjects: Have had bleeding events during the last 12 weeks, as documented in the subjects' medical records; or
   2. On-demand subjects: ≥ 3 bleeding episodes (spontaneous or traumatic) requiring exogenous FVIII therapy in the past 52 weeks;

6. No history of hypersensitivity or anaphylaxis associated with FVIII product administration;

7. Have no measurable FVII inhibitor as assessed by laboratory two times that were at least one week apart; or documented no prior history of FVIII inhibitor after 150 EDs and no clinical signs or symptoms of decreased response to FVIII infusion ;

8. Have acceptable laboratory values sampled at screening and repeated prior to Day 0; A. Hemoglobin ≥ 11 g/dL; B. Platelets ≥ 100 x 10^9/L; C. AST, ALT, alkaline phosphatase ≤ 1.25 upper limit of normal (ULN); D. Bilirubin ≤ 1.25 ULN; E. Creatinine ≤ 2 mg/dL.

9. Agree to use reliable barrier contraception until the end of the 52 weeks observation period, and three consecutive semen samples are negative for vector sequences after GS001 infusion.

Exclusion Criteria

1. Have Hepatitis B, hepatitis C or HBsAg, HCVAb, HBV-DNA, HCV-RNA are positive and have clinical significance. Both natural clearers and those who have cleared HCV on antiviral therapy are deemed eligible;
2. Currently Receiving antiviral therapy for hepatitis B and C;
3. Have underlying liver disease, as defined by previous diagnosis of portal hypertension, splenomegaly, hepatic encephalopathy, decrease of serum albumin and liver fibrosis ≥ 3 stage; or liver biopsy within the past 6 months confirmed METAVIR ≥ 3, FibroScan > 8.3 kPa, Fibro Test/Fibro SURE > 0.48, APRI > 1; Subject has any confirmed congenital or acquired immunodeficiency diseases (e.g., various common type of immunodeficiency diseases, human immunodeficiency virus [HIV] infection, organ transplantation) ;
4. Have Anti-AAV8 neutralizing antibody titer ≥ 1:16, anti-AAV8 binding antibody titer ≥ 1:400;
5. Have history of chronic infections or other chronic diseases that may pose a risk to the study participation;
6. Have participated in a previous gene therapy research trial within the last 52 weeks or in a clinical study with an investigational drug within the past 30 days;
7. The subject has any concurrent diseases that cannot tolerate treatments of prednisone or prednisolone as judged by the investigator;
8. History of arterial or venous thromboembolic events (e.g., deep vein thrombosis, non-hemorrhagic stroke, pulmonary embolism, myocardial infarction, arterial embolism);
9. Known inherited or acquired thrombophilia, including conditions associated with increased risk of thromboembolism, such as atrial fibrillation;
10. Major surgery planned in 1 year period following the infusion with GS001;
11. Hypersensitivity to the study vector;
12. Have clinically major diseases or any other unspecified conditions that, in the opinion of the Investigator, makes the subject unsuitable for participating in the study;
13. Patients who are unable or unwilling to comply with the schedule of visits and study assessments described in the clinical protocol;
14. Evidence of other bleeding disorders not associated with hemophilia A.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment group	Injection of GS001	Arm of GS001

Primary Outcome Measures

Name	Time	Method
Thrombosis risk assessment	From the start of study treatment (Day 1) through up to the end of study (about 5 years).	For any individual who reaches \>150% vector-derived FVIII: C activity levels following the infusion of GS001, laboratory parameters of thrombotic potential will be assessed.
Percentage of subjects in each dose group with newly occurred clinically significant abnormalities in physical examination compared to the baseline.	From the start of study treatment (Day 1) through up to the end of study (about 5 years).	The number of subjects in each dose group with clinically significant changes in physical examination compared to the baseline.
Changes of Weighted Mean of vital signs (systolic blood pressure [SBP] and diastolic blood pressure [DBP], pulse rate, temperature, respiratory rate) from baseline at each assessment time point for each dose group	From the start of study treatment (Day 1) through up to the end of study (about 5 years).	The vital signs (SBP, DBP, pulse rate, temperature, respiratory rate) of the subjects were measured. The maximum, minimum, and mean observed values of vital signs (SBP, DBP, pulse rate, temperature, respiratory rate) from the dosing (Day 1) to the end of the study were calculated for each subject.
Changes of Mean Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amio Transferase (AST) from baseline at each assessment time point for each dose group	From the start of study treatment (Day 1) through up to the end of study (about 5 years).	Blood samples of subjects were collected for the evaluation of liver function throughout this study. All of these parameters are measured to help assess the condition of the liver. For ALP, AST and ALT, the percentage of subjects with the worst post-treatment results in each dose group will be summarized as follows: \> 1.0 x ULN ≤ 1.5x ULN; \> 1.5 x ULN ≤ 3.0 x ULN; \> 3.0 x ULN ≤ 5.0 x ULN; \> 5.0 x ULN
Viral vector shedding of GS001	From date of infusion until the date of 3 consecutive documented negative results, assessed up to 1 year.	The vector shedding in serum, PMBC, saliva, urine, semen and feces will be monitored
Incidence of treatment- related adverse events	From screening through up to the end of study (about 5 years).	Number of patients experiencing treatment-related adverse events.
Immune response to FVIII transgene	From screening period through up to 5 years.	The changes of FVIII inhibitor and antibody levels
Immune response to AAV capsid proteins	From screening period through up to 5 years.	Changes in the expression levels of neutralizing and binding antibodies of AAV.

Secondary Outcome Measures

Name	Time	Method
Number of bleeding events requiring exogenous FVIII replacement therapy within 1 year after GS001 infusion	Week 3 to Week 52 post GS001 Infusion	Number of bleeding events (Spontaneous and Traumatic) requiring exogenous FVIII replacement therapy
Number of bleeding events within 1 year after GS001 infusion	Week 3 to Week 52 post GS001 infusion	Number of bleeding events (spontaneous or traumatic) including untreated bleeding events
Vector- derived FVIII:C and FVIII antigen levels	From pre-dose phase through up to 1 years post-dose	Vector- derived FVIII:C and FVIII antigen levels will be measured after dosing.
FVIII usage within 1 year after GS001 infusion	From week 3 to week 52 post GS001 infusion.	Number of FVIII replacement therapies and total utilization of exogenous FVIII (IU/kg) replacement therapy.

Trial Locations

Locations (1)

Chinese Academy of Medical Science and Blood Disease Hospital; 🇨🇳 Tianjin, Tianjin, China